The Total number of records shown on this page is 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_3220	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result73% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3221	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result60% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3222	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result55% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3223	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3224	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman bone osteosarcoma cell line	Cell line143-B	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result40% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3249	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3250	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3251	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result75% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3252	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result72% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3253	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result60% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3254	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman canine osteosarcoma	Cell lineD17	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result55% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3279	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman synovial sarcoma cell line	Cell lineSW982	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3280	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman synovial sarcoma cell line	Cell lineSW982	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3281	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman synovial sarcoma cell line	Cell lineSW982	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3282	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman synovial sarcoma cell line	Cell lineSW982	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result75% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3283	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman synovial sarcoma cell line	Cell lineSW982	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result70% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3284	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman synovial sarcoma cell line	Cell lineSW982	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result70% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3404	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.001 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3405	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.005 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3406	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3407	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.05 MOI	In-vitro result35% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3408	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3409	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3410	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.25 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3411	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3412	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.75 MOI	In-vitro result28% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3413	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration1 MOI	In-vitro result25% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3414	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3415	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.05 MOI	In-vitro result80% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3416	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result75% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3417	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result25% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3418	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration1 MOI	In-vitro result10% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3419	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3420	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.05 MOI	In-vitro result80% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3421	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result80% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3422	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result50% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3423	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3424	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (2 × 10⁻² micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3425	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (2 × 10⁻² micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3426	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine 3 × 10⁻² micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result50% of tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3427	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (3 × 10⁻² micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3428	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 × 10⁻¹ micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result60% of tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3429	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 × 10⁻¹ micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result55% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3430	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (7.5 × 10⁻² micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3431	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (7.5 × 10⁻² micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3432	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (1 × 10⁻² micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result25% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3433	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (1 × 10⁻² micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result50% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3434	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (5 × 10⁻³ micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result50% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3435	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (5 × 10⁻³ micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3436	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (1 × 10⁻² micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result30% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3437	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (1 × 10⁻² micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result50% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3438	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (5 × 10⁻³ micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result50% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3439	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (5 × 10⁻³ micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result60% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3440	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result70% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3441	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.03 MOI	In-vitro result60% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3442	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.05 MOI	In-vitro result52% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3443	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.01 MOI	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3444	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.03 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3445	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.05 MOI	In-vitro result30% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3446	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.5 MOI	In-vitro result60% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3447	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.75 MOI	In-vitro result55% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3448	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration1 MOI	In-vitro result55% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3449	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.5 MOI	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3450	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.75 MOI	In-vitro result45% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3451	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineMIAPaCa-2	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3452	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (10 nM)and gemcitabine (100 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.075 MOI	In-vitro result60% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3453	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (10 nM)and gemcitabine (100 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3454	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (10 nM)and gemcitabine (100 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.125 MOI	In-vitro result60% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3455	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (10 nM)and gemcitabine (100 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.075 MOI	In-vitro result45% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3456	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (10 nM)and gemcitabine (100 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.1 MOI	In-vitro result45% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3457	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (10 nM)and gemcitabine (100 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineAsPC-1	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.125 MOI	In-vitro result45% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3458	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (37.5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.075 MOI	In-vitro result75% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3459	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (37.5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result75% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3460	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (37.5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.125 MOI	In-vitro result72% cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3461	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (37.5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.075 MOI	In-vitro result72% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3462	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (37.5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3463	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (37.5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell linePANC-1	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.125 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3741	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.0001 MOI	In-vitro result100% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3742	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3743	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3744	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3745	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3746	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3747	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.0001 MOI	In-vitro result100% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3748	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3749	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3750	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3751	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3752	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3753	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.0001 MOI	In-vitro result100% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3754	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3755	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result98% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3756	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3757	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3758	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3759	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3760	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result50% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3761	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (5 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3762	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (5 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell linePANC-1	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result20% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3763	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineSW1990	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143